Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …
Black Friday is past. So is Cyber Monday.
Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …
Today, the FDA approved Theravance’s (TBPH) Yupelri (revefenacin) inhalation solution for the treatment of COPD. Thervance and Mylan (MYL) are partnered on the opportunity.
Did an iceberg just wallop into Omeros (OMER) stock? The drug maker’s shares are plunging at breakneck speed of almost 20%.
Shares of biotechnology company AcelRx (ACRX) are tumbling – down nearly 17% as of this writing. The reason?
Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert …
Advanced Micro Devices (AMD) shares rose nearly 4% yesterday after the chip giant’s Next Horizon event kicked off with the announcement that the first …
Amarin (AMRN) investors should expect material news on November 10, as that’s when the fish oil drug maker plans to release additional details from …
Investors weren’t impressed with Puma Biotechnology (PBYI) latest earnings report, and at least one Wall Street analyst has had enough. J.
